Mark Altmeyer is the founder of Arvelle Therapeutics. Arvelle Therapeutics has raised $100M in total funding. Latest round: Series A.
Mark Altmeyer is the Founder and CEO of Arvelle Therapeutics, a specialty neurology company focused on treating treatment-refractory epilepsy with its lead compound Cenobamate in Europe. He moved from big pharma into startups, highlighting his focus on data-driven compound selection and forming efficient teams in biotech.
Full founder directory · Investor directory · Company funding database · Fundraising library